Epicardial anchor devices and methods

Abstract
Apparatus and methods are described herein for anchoring a prosthetic heart valve. In some embodiments, an apparatus includes a tether attachment member that includes a base member that defines at least a portion of a tether passageway through which a portion of a tether extending from a prosthetic heart valve can be received therethrough. The base member defines a locking pin channel that intersects the tether passageway. A locking pin is disposable within the locking pin channel and movable between a first position in which the locking pin is at a spaced distance from the tether passageway, and a second position in which the locking pin intersects the tether passageway and can engage the portion of a tether disposed therein to secure the tether to the tether attachment member.
Description
BACKGROUND

Embodiments are described herein that relate to devices and methods for anchoring a medical device such as a prosthetic heart valve replacement.


Some known devices for anchoring a medical device, such as, for example, a prosthetic heart valve (e.g. mitral valve) can include securing one or more tethers extending from the medical device to body tissue. For example, one or more tethers can extend from a prosthetic heart valve through an opening in the ventricular wall of the heart. Some known methods of anchoring or securing the tethers can include the use of staples or other fasteners that engage or pierce tissue near the puncture site. Such devices can have relatively large profiles and be difficult to easily deliver percutaneously to the desired anchoring site. Some known methods of securing a prosthetic heart valve can include suturing the tethers extending from the valve to body tissue, or tying the suture ends. Such devices and methods can be difficult to maneuver to secure the tether(s) with a desired tension,


Further, when an opening is made directly into the ventricular wall or apex of a heart, such as when a prosthetic valve is percutaneously delivered and deployed, in addition to securing the prosthetic valve in a proper position, the efficacy of sealing the puncture site is critical to the life of the patient since hemodynamic losses from a cardiac puncture can cause shock and death within minutes. Further, the outward pressure that the puncture site is subjected to when it is located in the heart muscle itself is much higher than puncture sites that are distal to the heart. Accordingly, improved devices and methods for securing a prosthetic heart valve and for engaging and closing tissue, e.g., to close a cardiac puncture site, would be considered useful to solve these and other problems known in the art.


SUMMARY

Apparatus and methods for anchoring a prosthetic heart valve are described herein. In some embodiments, an apparatus includes a tether attachment member that includes a base member that defines at least a portion of a tether passageway through which a portion of a tether extending from a prosthetic heart valve can be received therethrough. The base member defines a locking pin channel that intersects the tether passageway. A locking pin is disposable within the locking pin channel and movable between a first position in which the locking pin is at a spaced distance from the tether passageway, and a second position in which the locking pin intersects the tether passageway and can engage the portion of a tether disposed therein to secure the tether to the tether attachment member.





BRIEF DESCRIPTION OF THE DRAWINGS


FIG. 1 is a cross-sectional illustration of portion of a heart with a prosthetic mitral valve implanted therein and an epicardial anchor device anchoring the mitral valve in position.



FIG. 2 is a schematic illustration of an epicardial anchor device, according to an embodiment.



FIG. 3 is a side view of an epicardial anchor device, according to an embodiment.



FIG. 4 is an exploded side view of the epicardial anchor device of FIG. 3.



FIG. 5 is a side view of the epicardial anchor device of FIG. 3 shown disposed at a spaced distance from a puncture site in an epicardial surface of a ventricular wall and showing a sleeve gasket of the epicardial anchoring device in an uncompressed state or configuration.



FIG. 6 is a side view of the epicardial anchor device and ventricular wall of FIG. 5, shown with the anchoring device compressed against the puncture site and ventricular wall and the gasket in a compressed state or configuration.



FIG. 7 is an exploded side view of an epicardial anchor device, according to another embodiment.



FIG. 8 is an exploded side view of an epicardial anchor device, according to another embodiment.



FIG. 9 is a top view of a flexible pad that can be included in an epicardial anchor device, according to an embodiment.



FIG. 10 is a perspective view of the flexible pad of FIG. 9 and a portion of a tether disposed therethrough.



FIG. 11 is a perspective view of a locking pin and a tether attachment member, according to an embodiment.



FIG. 12 is a bottom perspective view of the tether attachment member of FIG. 11.



FIG. 13 is a top perspective view of a tether attachment member that can be used within an anchor device, according to an embodiment, with a lever arm shown in a first position.



FIG. 14 is a cross-sectional perspective view of the tether attachment member of FIG. 13 with the lever arm shown in the first position.



FIG. 15 is a cross-sectional side view of the tether attachment member of FIG. 13 with the lever arm shown in the first position and a portion of a tether extending through the device.



FIG. 16 is a cross-sectional side view of the tether attachment member of FIG. 13 with the lever arm shown in a second position and a portion of a tether extending through the device.



FIG. 17 is a cross-sectional perspective view of a tether attachment member, according to an embodiment, with an access arm of the anchor device shown in a first position and a portion of a tether extending through the device.



FIG. 18 is a side-cross-sectional view of the tether attachment member of FIG. 17 shown with the access arm in the first position and the portion of a tether extending through the device.



FIG. 19 is a perspective view of the tether attachment member of FIG. 17 with a delivery device coupled thereto.



FIG. 20 is an enlarged view of the tether attachment member and a portion of the delivery device of FIG. 19.



FIG. 21 is a top perspective view of the tether attachment member of FIG. 17 with the access arm shown in a second position.



FIG. 22 is a top perspective view of an epicardial anchor device, according to another embodiment.



FIG. 23 is a top view of the epicardial anchor device of FIG. 22.



FIG. 24 is an exploded view of the epicardial anchor device of FIG. 22.



FIG. 25 is a cross-sectional perspective view of the epicardial anchor device of FIG. 22 with a locking pin of the device shown in a first position.



FIG. 26 is a cross-sectional side view of the epicardial anchor device of FIG. 20 with the locking pin of the device shown in the first position.



FIG. 27 is a cross-sectional bottom perspective view of the epicardial anchor device of FIG. 22 with the locking pin shown in a second position.



FIGS. 28 and 29 are a top perspective and a bottom perspective view, respectively, of a hub member of the epicardial anchor device of FIG. 22.



FIG. 30 is an enlarged top view of a portion of the pericardial pad device of FIG. 22.



FIG. 31 is a perspective view of the epicardial anchor device of FIG. 22 with a delivery device coupled thereto.





DETAILED DESCRIPTION

Apparatus and methods are described herein that can be used for securing and anchoring a prosthetic heart valve, such as, for example, a prosthetic mitral valve. Apparatus and methods described herein can also be used to close openings through the heart formed for example, when performing a procedure to implant a prosthetic heart valve. Apparatus and methods described herein can also be used to anchor other medical devices and/or to close punctures or openings in other body lumens formed during a diagnostic or therapeutic procedure.


In some embodiments, an apparatus includes a tether attachment member that includes a base member that defines at least a portion of a tether passageway through which a portion of a tether extending from a prosthetic heart valve can be received therethrough. The base member defines a locking pin channel that intersects the tether passageway. A locking pin is disposable within the locking pin channel and movable between a first position in which the locking pin is at a spaced distance from the tether passageway, and a second position in which the locking pin intersects the tether passageway and can engage the portion of a tether disposed therein to secure the tether to the tether attachment member.


In some embodiments, an apparatus includes a tether attachment member that includes a base member and a lever arm movably coupled to the base member. The base member and the lever arm collectively define a tether passageway through which a portion of a tether extending from a prosthetic heart valve can be received therethrough. The base member defines a locking pin channel that intersects the tether passageway and is in fluid communication therewith, and a locking pin is disposed within the locking pin channel. The lever arm is configured to be moved from a first position in which the portion of the tether can be inserted into the tether passageway, and a second position in which the locking pin secures a tether disposed within the tether passageway to the tether attachment member.


In some embodiments, an apparatus includes a tether attachment member that includes a base member and a hub member rotatably coupled to the base member. The base member and the hub each define at least a portion of a tether passageway through which a portion of a tether extending from a prosthetic heart valve can be received therethrough. The base member defines a locking pin channel that intersects the tether passageway and is in fluid communication therewith and a locking pin is disposed at least partially within the locking pin channel. The hub defines a cam channel in which a driver portion of the locking pin is received. The hub is configured to rotate relative to the base member such that the cam channel moves the locking pin linearly within the locking pin channel moving the locking pin from a first position in which the locking pin is at a spaced distance from the tether passageway, and a second position in which the locking pin intersects the tether passageway and engages a portion of a tether disposed therein to secure the tether to the tether attachment member.


In some embodiments, a method includes inserting into a tether passageway defined by a tether attachment member, a portion of a tether extending from a prosthetic heart valve. The tether attachment member is disposed adjacent an opening in a ventricular wall of a heart from which the tether extends. The tether attachment member is actuated such that a locking pin disposed within a locking pin channel defined by the tether attachment member intersects the tether passageway and engages a portion of the tether disposed within the tether passageway, securing the tether to the tether attachment member.


As used in this specification, the singular forms “a,” “an” and “the” include plural referents unless the context clearly dictates otherwise. Thus, for example, the term “a member” is intended to mean a single member or a combination of members, “a material” is intended to mean one or more materials, or a combination thereof.


As used herein, the words “proximal” and “distal” refer to a direction closer to and away from, respectively, an operator of, for example, a medical device. Thus, for example, the end of the medical device closest to the patient's body (e.g., contacting the patient's body or disposed within the patient's body) would be the distal end of the medical device, while the end opposite the distal end and closest to, for example, the user (or hand of the user) of the medical device, would be the proximal end of the medical device.


In some embodiments, an epicardial pad system is described herein that can be used to anchor a compressible prosthetic heart valve replacement (e.g., a prosthetic mitral valve), which can be deployed into a closed beating heart using a transcatheter delivery system. Such an adjustable-tether and epicardial pad system can be deployed via a minimally invasive procedure such as, for example, a procedure utilizing the intercostal or subxyphoid space for valve introduction. In such a procedure, the prosthetic valve can be formed in such a manner that it can be compressed to fit within a delivery system and secondarily ejected from the delivery system into the target location, for example, the mitral or tricuspid valve annulus.


A compressible prosthetic mitral valve can have a shape, for example that features a tubular stent body that contains leaflets and an atrial cuff. This allows the valve to seat within the mitral annulus and be held by the native mitral leaflets. The use of a flexible valve attached using an apical tether can provide compliance with the motion and geometry of the heart. The geometry and motion of the heart are well-known as exhibiting a complicated biphasic left ventricular deformation with muscle thickening and a sequential twisting motion. The additional use of the apically secured ventricular tether helps maintain the prosthetic valve's annular position without allowing the valve to migrate, while providing enough tension between the cuff and the atrial trabeculations to reduce, and preferably eliminate, perivalvular leaking. The use of a compliant valve prosthesis and the special shape and features can help reduce or eliminate clotting and hemodynamic issues, including left ventricular outflow tract (LVOT) interference problems. Many known valves are not able to address problems with blood flow and aorta/aortic valve compression issues.


Structurally, the prosthetic heart valve can include: a self-expanding tubular frame having a cuff at one end (the atrial end); one or more attachment points to which one or more tethers can be attached, preferably at or near the ventricular end of the valve; and a leaflet assembly that contains the valve leaflets, which can be formed from stabilized tissue or other suitable biological or synthetic material. In one embodiment, the leaflet assembly may include a wire form where a formed wire structure is used in conjunction with stabilized tissue to create a leaflet support structure, which can have anywhere from 1, 2, 3 or 4 leaflets, or valve cusps disposed therein. In another embodiment, the leaflet assembly can be wireless and use only the stabilized tissue and stent body to provide the leaflet support structure, and which can also have anywhere from 1, 2, 3 or 4 leaflets, or valve cusps disposed therein.


The upper cuff portion may be formed by heat-forming a portion of a tubular nitinol structure (formed from, for example, braided wire or a laser-cut tube) such that the lower portion retains the tubular shape but the upper portion is opened out of the tubular shape and expanded to create a widened collar structure that may be shaped in a variety of functional regular or irregular funnel-like or collar-like shapes.


A prosthetic mitral valve can be anchored to the heart at a location external to the heart via one or more tethers coupled to an anchor device, as described herein. For example, the tether(s) can be coupled to the prosthetic mitral valve and extend out of the heart and be secured at an exterior location (e.g., the epicardial surface) with an anchor device, as described herein. An anchor device as described herein can be used with one or more such tethers in other surgical situations where such a tether may be desired to extend from an intraluminal cavity to an external anchoring site.



FIG. 1 is a cross-sectional illustration of the left ventricle LV and left atrium LA of a heart having a transcatheter prosthetic mitral valve PMV deployed therein and an epicardial anchor device EAD as described herein securing the prosthetic mitral valve PMV in place. FIG. 1 illustrates the prosthetic mitral valve PMV seated into the native valve annulus and held there using an atrial cuff AC of the prosthetic mitral valve PMV, the radial tension from the native leaflets, and a ventricular tether T secured with attachment portions Tp to the prosthetic mitral valve PMV and to the epicardial anchor EAD. Various embodiments of an epicardial anchor device are described in more detail below with reference to specific embodiments.



FIG. 2 is a schematic illustration of an epicardial anchor device 100 (also referred to herein as “anchor device” or “epicardial anchor”) according to an embodiment. The anchor device 100 can be used to anchor or secure a prosthetic mitral valve PMV deployed between the left atrium and left ventricle of a heart. The anchor device 100 can be used, for example, to anchor or secure the prosthetic mitral valve PMV via a suturing tether 128 as described above with respect to FIG. 1. The anchor device 100 can also seal a puncture formed in the ventricular wall (not shown in FIG. 2) of the heart during implantation of the prosthetic mitral valve PMV. The anchor device 100 can also be used in other applications to anchor a medical device (such as any prosthetic atrioventricular valve or other heart valve) and/or to seal an opening such as a puncture.


The anchor device 100 can include a pad (or pad assembly) 120, a tether attachment member 124 and a locking pin 126. In some embodiments, the anchor device 100 can include a sleeve gasket (not shown in FIG. 2) as described with respect to FIGS. 3-6. The pad 120 can contact the epicardial surface of the heart and can be constructed of any suitable biocompatible surgical material. The pad 120 can be used to assist the sealing of a surgical puncture formed when implanting a prosthetic mitral valve. In some embodiments, the pad 120 can include a slot that extends radially to an edge of the pad 120 such that the pad 120 can be attached to, or disposed about, the tether 128 by sliding the pad 120 onto the tether 128 via the slot. Such an embodiment is described below with respect to FIGS. 9 and 10.


In some embodiments, the pad 120 can be made with a double velour material to promote ingrowth of the pad 120 into the puncture site area. For example, pad or felt pledgets can be made of a felted polyester and may be cut to any suitable size or shape, such as those available from Bard® as PTFE Felt Pledgets having a nominal thickness of 2.87 mm. In some embodiments, the pad 120 can be larger in diameter than the tether attachment member 124. The pad 120 can have a circular or disk shape, or other suitable shapes.


The tether attachment member 124 can provide the anchoring and mounting platform to which one or more tethers 128 can be coupled (e.g., tied or pinned). The tether attachment member 124 can include a base member (not shown) that defines at least a portion of a tether passageway (not shown) through which the tether 128 can be received and pass through the tether attachment member 124, and a locking pin channel (not shown) through which the locking pin 126 can be received. The locking pin channel can be in fluid communication with the tether passageway such that when the locking pin 126 is disposed in the locking pin channel, the locking pin 126 can contact or pierce the tether 128 as it passes through the tether passageway as described in more detail below with reference to specific embodiments.


The locking pin 126 can be used to hold the tether 128 in place after the anchor device 100 has been tightened against the ventricular wall and the tether 128 has been pulled to a desired tension. For example, the tether 128 can extend through a hole in the pad 120, through a hole in a sleeve gasket (if the anchor device includes a sleeve gasket), and through the tether passageway of the tether attachment member 124. The locking pin 126 can be inserted or moved within the locking pin channel 134 such that it pierces or otherwise engages the tether 128 as the tether 128 extends through the tether passageway of the tether attachment member 124. Thus, the locking pin 126 can intersect the tether 128 and secure the tether 128 to the tether attachment member 124.


The tether attachment member 124 can be formed with, a variety of suitable biocompatible material. For example, in some embodiments, the tether attachment member 124 can be made of polyethylene, or other hard or semi-hard polymer, and can be covered with a polyester velour to promote ingrowth. In other embodiments, the tether attachment member 124 can be made of metal, such as, for example, Nitinol®, or ceramic materials. The tether attachment member 124 can be various sizes and/or shapes. For example, the tether attachment member 124 can be substantially disk shaped.


In some embodiments the tether attachment member 124 can include a lever arm (not shown in FIG. 2) that can be moved between an open position to load the tether 128 within the tether attachment member 124, and a closed position to secure the tether 128 to the tether attachment member 124. For example, in some embodiments, when the lever arm is moved to the closed position, the tether passageway is brought into an intersecting relation with the locking pin channel such that the locking pin 126 engages the tether 128 disposed within the tether passageway. In some embodiments, when the lever arm is in the open position, a tool can be used to move the locking pin within the locking pin channel such that the locking pin engages the tether 128 disposed within the tether passageway. In such an embodiment, after the locking pin 126 secures the tether 128, the lever arm can be moved to the closed position.


In some embodiments, the tether attachment member 124 can include a hub that is movably coupled to the base member of tether attachment member 124. The hub can define a channel that can receive a portion of the locking pin (or locking pin assembly) 126 such that as the hub is rotated, the hub acts as a cam to move the locking pin 126 linearly within the locking pin channel. As with previous embodiments, as the locking pin 126 is moved within the locking pin channel, the locking pin can engage or pierce the tether 128 disposed within the tether passageway and secure the tether 128 to the tether attachment member 124. Such an embodiment is described herein with respect to FIGS. 22-31.


In use, after a PMV has been placed within a heart, the tether extending from the PMV can be inserted into the tether passageway of the anchor device 100 and the tension on the tether attachment device can be adjusted to a desired tension. Alternatively, in some cases, the tether extending from the PMV can be coupled to the anchor device 100 prior to the PMV being placed within the heart. The anchor device 100 (e.g., some portion of the anchor device such as the tether attachment member 124, or the lever arm or hub depending on the particular embodiment) can be actuated such that the locking pin 126 intersects the tether passageway and engages a portion of the tether disposed within the tether passageway, securing the tether to the tether attachment member. In some embodiments, prior to inserting the tether into the tether passageway, the anchor device 100 can be actuated to configure the anchor device 100 to receive the tether. For example, if the tether attachment member includes a lever arm movably coupled to the base member, the lever arm may need to be moved to an open position to allow the tether to be inserted. In some embodiments, the anchor device 100 can be actuated by rotating a hub relative to a base member of the tether attachment member 124 such that the locking pin 126 is moved from a first position in which the locking pin is spaced from the tether passageway and a second position in which the locking pin intersects the tether passageway and engages or pierces the portion of the tether.


One implementation of the epicardial anchor device 100 is shown in FIGS. 3-6. An epicardial anchor device 200 (also referred to herein as “anchor device” or “epicardial anchor”) can include a flexible pad 220, a sleeve gasket 222, a tether attachment member 224 and a locking pin 226 (shown in FIG. 4). The anchor device 200 can be used to anchor or secure a prosthetic mitral valve (not shown in FIGS. 3-6) via a suturing tether 228 shown in FIGS. 5 and 6. The anchor device 200 can also seal a puncture 230 formed in the ventricular wall V (see FIGS. 5 and 6) of the heart during implantation of the prosthetic mitral valve.


The flexible pad 220 (also referred to herein as “pad”) can contact the epicardial surface of the heart and can be constructed of any suitable biocompatible surgical material. The pad 220 can be used to assist the sealing of a surgical puncture (e.g., puncture 230) formed when implanting a prosthetic mitral valve. The pad 220 can be made with the same or similar materials as described above for pad 120, and can be various sizes and shapes. The pad 220 is shown as having a circular or disk shape, however it should be understood that other suitable shapes can alternatively be used. The pad 220 defines a hole 225 (see FIGS. 4 and 6) through which the tether 228 (shown in FIGS. 5 and 6) can be received as described in more detail below.


The sleeve gasket 222 can be disposed between the pad 220 and the tether attachment member 224 and can be used to seal a gap or leakage that may occur between the pad 220 and the tether attachment member 224. The sleeve gasket 222 can be made of, for example, a flexible material such that it can be compressed when the tether attachment member 224 and/or pad 220 are tightened against the puncture site, e.g. against the ventricular wall. The sleeve gasket 222 may be a separate component coupled to the pad 220 and the tether attachment member 224 or can be formed integrally or monolithically with the pad 220 and/or the tether attachment member 224. The sleeve gasket 222 can be used to prevent hemodynamic leakage that may flow along the path of the suturing tether 228. The sleeve gasket 222 can also define a hole (not shown) through which the tether 228 can be received.


The tether attachment member 224 can provide the anchoring and mounting platform to which one or more tethers 228 (see FIGS. 5 and 6) may be coupled (e.g., tied). The tether attachment member 224 includes a base member 240 that defines an axial tether passageway 235 through which the tether 228 can be received and pass through the tether attachment member 224, and a locking pin channel 234 through which the locking pin 226 can be received. The locking pin channel 234 can be in fluid communication with the tether passageway 235 such that when the locking pin 226 is disposed in the locking pin channel 234, the locking pin 226 can contact the tether 228 as it passes through the tether passageway 235 as described in more detail below. The locking pin 226 can be used to hold the tether 228 in place after the anchor device 200 has been tightened against the ventricular wall V. For example, the tether 228 can extend through the hole 225 of the pad 220, through the hole (not shown) of the sleeve gasket 222, and through the tether passageway 235 of the tether attachment member 224. The locking pin 226 can be inserted through the locking pin channel 234 such that it pierces the tether 228 as the tether 228 extends through the tether passageway 235 of the tether attachment member 224. Thus, the locking pin 226 can laterally intersect the tether 228 and secure the tether 228 to the tether attachment member 224.


The tether attachment member 224 can be made of any suitable biocompatible material. For example, in some embodiments, the tether attachment member 224 can be made of polyethylene, or other hard or semi-hard polymer, and can be covered with a polyester velour to promote ingrowth. In other embodiments, the tether attachment member 224 can be made of metal, such as, for example, Nitinol®, or ceramic materials. The tether attachment member 224 can be various sizes and/or shapes. For example, the tether attachment member 224 can be substantially disk shaped.


In some embodiments, the tether attachment member 224 can be substantially disk shaped and have a diameter between, for example, 1.0-3.0 cm. In other embodiments, the tether attachment member 224 can have a diameter, for example, between 0.2-5.0 cm. For example, a larger size tether attachment member 224 may be desirable to use in, for example, a hernia repair, gastrointestinal repairs, etc.


The disk shape of the tether attachment member 224 used to capture and anchor a suture can also be used with little or no trauma to the tissue at the site of the anchor, unlike suture anchors that bore into tissue with screws or barbs. Further, the disk shaped tether attachment member 224 can be easily and quickly slid over the tether 228, instead of using stitches, which can allow for the effective permanent closure of large punctures. Surgically closing large punctures by sewing can be time consuming and difficult. When closing a puncture in the heart, adding the difficulty of requiring a surgeon to sew the puncture closed can increase the likelihood of life threatening complications to the patient. This is especially so in a situation where a prosthetic heart valve is delivered and deployed without opening the chest cavity using transcatheter technologies. Sewing a ventricular puncture closed in this situation may be undesirable.



FIGS. 5 and 6 illustrate the tether 228 extending through the puncture site 230 within a left ventricular wall V of a heart and coupled to the anchor device 200. FIG. 5 illustrates the anchor device 200 prior to being tightened against the epicardial surface of the ventricular wall V, and the sleeve gasket 222 in an uncompressed state or configuration. The tether 228 can optionally be wound around the tether attachment member 224 to further improve anchoring.



FIG. 6 illustrates the anchor device 200 tightened against the epicardial surface of the ventricular wall V. As shown in FIG. 6, the anchor device 200 can be compressed against the puncture site 230 and contact the epicardial surface. An end portion 232 (shown in FIG. 5) of the tether 228 can be trimmed after the tether 228 has been secured to the tether attachment member 224 or after the anchor device 200 has been secured against the epicardial surface.



FIG. 7 illustrates an embodiment of an epicardial anchor device 300 (also referred to herein as “anchor device” or “epicardial anchor”) that is similar to the anchor device 200 except the anchor device 300 does not include a sleeve gasket (e.g., sleeve gasket 222 described above). The anchor device 300 can include a flexible pad 320, a tether attachment member 324 and a locking pin 326, which can be configured the same as or similar to the flexible pad 220, the tether attachment member 224 and the locking pin 226, respectively, described above. The anchor device 300 can be used the same as or similar to anchor device 200 to secure a prosthetic mitral valve (not shown) via a suturing tether (not shown). The anchor device 300 may be desirable to use, for example, when an anti-leakage sleeve is unnecessary to prevent hemodynamic leakage that may flow along the path of the suturing tether.



FIG. 8 illustrates an embodiment of an epicardial anchor device 400 (also referred to herein as “anchor device” or “epicardial anchor”) that is similar to the anchor device 200 and the anchor device 300 except the anchor device 400 does not include a pad (e.g., pads 220 and 320). The anchor device 400 can include a tether attachment member 424, a sleeve gasket 422 and a locking pin 426, which can be configured the same as or similar to the tether attachment member 224, the sleeve gasket 222 and the locking pin 226, respectively, described above. The anchor device 400 can be used to anchor or secure a prosthetic mitral valve (not shown) via a tether (not shown) in the same or similar manner as described above for previous embodiments. The anchor device 400 may be desirable to use, for example, when a flexible pad is unnecessary, for example, when the tether is moved to a new location. In such a case, the ventricular puncture would be small (e.g., a small diameter) and may not require the pad for bleeding control.



FIGS. 9 and 10 illustrate an embodiment of a pad 520 that can be included in an epicardial anchor device as described herein. The pad 520 defines an axial hole 525 and a slot 537 that communicates with hole 525. The slot 537 extends radially to an outer edge of the pad 520 such that the pad 520 can be disposed about or removed from a tether 528 (see FIG. 10) without sliding the pad 520 down the length of tether 528. For example, the pad 520 can be disposed about the tether 528 by laterally sliding the pad 520 from the side such that the tether is inserted into the slot 537 and positioned within the opening 525 of the pad 520. The pad 520 can be secured to the tether with, for example, pins, clamps, etc.


To remove the pad 520, the pad 520 can similarly slide off from the side, for example, outside of the apex of the ventricle of the heart. Thus, the pad 520 can be removed without removing the entire anchor device. The pad 520 can be formed with the same or similar materials as described above for previous embodiments (e.g., pad 220, 320, 420), and can be used to close a puncture site (e.g., in a ventricular wall) as described above.


The pad 520 can also enable the use of an introducer sheath at the apex, which would limit the amount of motion and passes through the apex. For example, when the sheath is pulled back, a slotted pad 520 can be slid in from the side allowing control of the tether tension during sheath removal. The pad 520 with slot 537 can also be used independent of a sheath as described above.



FIGS. 11 and 12 illustrate an embodiment of a tether attachment member 624 that can be included within an anchor device as described herein. Various features described herein for tether attachment member 624 can also be included in the tether attachment members described herein for other embodiments (e.g., 124, 224, 324, 424). As described above, a locking pin 626 (shown in FIG. 11) can be used to secure a tether/suture to the tether attachment member 624 in a similar manner as described above for previous embodiments.


The tether attachment member 624 is shown having a disk shape and can include a base member 640 that defines a winding channel 632, an axial tether passageway 635, radial channels 633, and a locking pin channel 634 through which the locking pin 626 can be received. The base member 640 also defines a proximal opening 615 and a distal opening 617 each communicating with the tether passageway 835. The base member 640 can include a chamfered edge or lead-in portion 627 at the proximal opening 615, and a chamfered edge or lead-in portion 629 at the distal opening 617 to allow a suture (e.g., tether) to be easily threaded into the tether passageway 635 and reduce lateral cutting force of the tether attachment member 624 against the suture. The radial channels 633 can allow a user to quickly capture and seat a tether (not shown) that is intended to be anchored. The winding channel 632 can allow a user to quickly wind tether(s) around tether attachment member 624. The use of winding channel 632 with radial channel(s) 633 can allow a user to quickly anchor the tether while permitting the user to unwind and recalibrate the anchor device to adjust the tension on the tether (not shown) as appropriate for a particular use.



FIGS. 13-16 illustrate a portion of another embodiment of an epicardial anchor device 700. The epicardial anchor device 700 includes a tether attachment member 724 and a flexible pad or fabric member (not shown in FIGS. 13-16). The tether attachment member 724 includes a base member 740 that defines a locking pin channel 734 that can receive therein a locking pin 726 in a similar manner as described above for previous embodiments and a circumferential pad channel 742. The pad channel 742 can be used to secure the flexible pad or fabric member (not shown in FIGS. 13-16) of the epicardial anchor device 700 to the tether attachment member 724. For example, the flexible pad can be disposed on a distal end portion of the tether attachment member 724 such that when the anchor device 700 is secured to a ventricular wall as described above for previous embodiments, the flexible pad contacts the ventricular wall.


The tether attachment member 724 also defines tether passageway 735 through which a tether 728 (see, e.g., FIGS. 15 and 16) can be received, and a proximal opening 715 and a distal opening 717 each in communication with the tether passageway 735. A chamfered edge or lead-in portion 729 is included at or near the distal opening 717 to allow a tether 728 (see e.g., FIGS. 15 and 16) to be easily threaded into the tether passageway 735 and reduce lateral cutting force of the tether attachment member 724 against the tether 728.


A lever arm 738 is coupled to the base member 740 that collectively with the base member 740 defines a tether passageway 735. The lever arm 738 can be moved between a first position, as shown in FIG. 16, in which the lever arm 738 is biased by a spring member 739 into a down position, and a second position, as shown in FIGS. 13-15, in which the lever arm 738 is placed in an extended position to allow the tether 728 to be placed within the tether passageway 735. For example, the lever arm 738 can be rotated in the direction of arrow A shown in FIG. 15 to move the lever arm 738 to its second or extended position. In some cases, a suture or cord can be used to pull the lever arm 738 to the extended second position.


When in the first position, as shown, for example, in FIGS. 14 and 15, a tip of the locking pin 726 is disposed at a spaced distance from the lever arm 738 and the tether passageway 735. When the locking pin 726 is spaced from the tether passageway 735, the tether 728 can be inserted into the tether passageway 735 as shown in FIG. 15. The tether 728 can then be tightened to a desired tension and the lever arm can then be released such that it is biased back to the first position, as shown in FIG. 16. When the lever arm 738 is moved (e.g., biased) to the first position, and with the tether 728 extending through the tether passageway 735, the locking pin 726 pierces or intersects with the tether 728 and the tip of the locking pin is then disposed within a cavity 736 defined by the lever arm 738 securing the tether 728 to the tether attachment member 724.



FIGS. 17-21 illustrate a portion of another embodiment of an epicardial anchor device 800 that includes a tether attachment member 824 and a flexible pad or fabric member (not shown in FIGS. 17-21). The tether attachment member 824 includes a base member 840 and a lever arm 838 pivotally coupled to the base member 840. The base member 840 defines a circumferential pad channel 842 in which the flexible pad can be coupled to the tether attachment member 824. For example, the flexible pad can be disposed on a distal end portion of the tether attachment member 824 such that when the anchor device 800 is secured to a ventricular wall as described above for previous embodiments, the flexible pad contacts the ventricular wall.


The lever arm 838 and the base member 840 collectively define a tether passageway 835 through which a tether 828 can be received, as shown in FIG. 17. The base member 840 also defines a distal opening 817 and an opening 815 each in fluid communication with the tether passageway 835. The tether 828 can be inserted through the distal opening 817 (the side to be implanted closest to the ventricular wall) and extend through a portion of the tether passageway 835 defined by the base member 840, and through a portion of the tether passageway 835 defined by the lever arm 838, and exit the opening 815. As with previous embodiments, the base member 840 includes a chamfered edge or lead-in portion 829 at the distal opening 817 of the tether passageway 835 to allow the tether 828 to be easily threaded into the tether passageway 835 and reduce lateral cutting force of the tether attachment member 824 against the tether 828.


The lever arm 838 defines a locking pin channel 844 in which a locking pin 826 can be movably disposed. The locking pin 826 includes a driver portion 846 and a piercing portion 849. As shown in FIGS. 17 and 18, the locking pin channel 844 includes portions with varying diameters in which the driver portion 846 of the locking pin 826 can be movably disposed. For example, the driver portion 846 can be threadably coupled to the inner walls of the locking pin channel 844 such that the locking pin 826 can be moved between a first position, shown in FIG. 17, in which the driver portion 846 is disposed within a portion 839 of the locking pin channel 844 and the piercing portion 849 is spaced from the tether passageway 835, and a second position in which the driver portion 846 is disposed within a portion 845 (shown in FIGS. 17 and 18) of the locking pin channel 834, and the piercing portion 849 extends through the tether passageway 835, engaging or piercing the tether 828. The lever arm 838 also defines an opening 847 that communicates with the locking pin channel 844 and can receive a driving tool that can be used to move the locking pin 826 within the locking pin channel 844 as described in more detail below.


The lever arm 838 can be moved (e.g., rotated, pivoted) between a first or open position, as shown, for example, in FIGS. 17 and 18, in which the lever arm 838 extends in a proximal direction from the base member 840, and a second or closed position as shown in FIG. 21, in which a proximal surface 819 of the lever arm 838 is substantially flush with a proximal surface 821 of the base member 840. When the lever arm 838 is in the first or open position, a delivery tool 848 can be coupled to the lever arm 828 as shown in FIGS. 19 and 20. The delivery tool 848 can include a driver 849 shown in FIG. 18 (e.g., a screw driver) that can engage the driver portion 846 of the locking pin 826 to move the locking pin 826 within the locking pin channel 834.


In operation, the tether 828 can be inserted into the tether passageway 835 and extend out of the opening 815 and within the delivery tool 848. The tether 828 can then be tightened to a desired tension. With the tether 828 at the desired tension, the driver 849 of the delivery tool 848 can then move the locking pin 826 from the first position, as shown in FIG. 17 to the second position in which the piercing portion 849 pierces or engages the tether 828, securing the tether 828 to the tether attachment member 824. For example, the driver 849 of the delivery tool 848 can threadably move the locking pin 826 from the first position to the second position. After the tether 828 is secured to the tether attachment member 824, the delivery tool 849 can be removed and the lever arm 838 can be moved to the second or closed position as shown in FIG. 21.



FIGS. 22-30 illustrate an epicardial anchor device according to another embodiment. An epicardial anchor device 900 includes a tether attachment member 924, a pad assembly 920, a tube member 955 and a tube cover member 956. The tether attachment member 924 includes a base member 940, a hub 950, a retaining ring 952, a locking pin assembly 926, and a pin member 953. The locking pin assembly 926 includes a driver portion 946 and a piercing portion 949. The base member 940 defines a circumferential pad channel 942, a retaining channel 951 and a locking pin channel 934. The pad channel 942 can be used to couple the pad assembly 920 to the tether attachment member 924. The retaining channel 951 can receive an outer edge of the retaining ring 952, which is used to retain the hub 950 to the base member 940. The base member 940 also defines cutouts or detents 943, as shown for example, in FIGS. 23, 25 and 30.


The tube member 955 is coupled to the base member 940 and the base member 940, the hub 950 and the tube member 955 collectively define a tether passageway 935 through which a tether (not shown) can be received. The cover member 956 can be formed with a fabric material, such as for example, Dacron®. The tether channel 935 intersects the locking pin channel 934 and is in fluid communication therewith.


The pad assembly 920 includes a top pad portion 958, a bottom pad portion 959 and a filler member 957 disposed therebetween. The top pad portion 958 and the bottom pad portion 959 can each be formed with, for example, a flexible fabric material. The top pad portion 958 and the bottom pad portion 959 can each define a central opening through which the tube member 955 can pass through. A portion of the top pad portion 958 is received within the channel 942 of the base member 940 as shown, for example, in FIGS. 25-27.


An outer perimeter portion of the hub 950 is received within the retaining channel 951 such that the hub 950 can rotate relative to the base member 940 to actuate the locking pin assembly 926 as described in more detail below. As shown, for example, in FIGS. 28 and 29, the hub 950 includes arms 961 with protrusions 962. The protrusions 962 can be received within cutouts 943 of the base member 940 and act as a stop or limit to the rotation of the hub 950. The slots 963 defined by the hub 950 enable the arms 961 to flex and allow the protrusions 962 to be moved in and out of the cutouts 943. As shown, for example, in FIGS. 27 and 29 the hub 950 defines a curved channel 960 on a bottom portion of the hub 950. The curved channel 960 is asymmetrical (or spiral) and receives the driver portion 946 of the locking pin assembly 926. As the hub 950 is rotated relative to the base member 940, the hub 950 acts as a cam to move the locking pin assembly 926 linearly within the locking pin channel 934. The locking pin assembly 926 can be moved from a first position in which the piercing portion 949 is disposed outside of the tether passageway 935 as shown in FIGS. 25 and 26, and a second position in which the piercing portion 949 extends through the tether passageway 935 as shown in FIG. 27. The pin member 953 (see, e.g., FIG. 26) can be formed with a metal material that is more radio-opaque than the other components of the anchor device and thus visible to the user (e.g. physician) using conventional imaging modalities to enable the user to confirm that the locking pin assembly 926 has been fully moved to the second position.


In use, when the locking pin assembly 926 is in the first position, a tether (not shown) coupled to, for example, a prosthetic mitral valve and extending through a puncture site in the ventricular wall of a heart can be inserted through the tether passageway 935. The hub 950 can then be rotated 180 degrees to move the locking pin assembly 926 linearly within the locking pin channel 934 such that the piercing portion 949 extends through the tether passageway 935 and engages or pierces the tether, securing the tether to the tether attachment member 924. For example, when the locking pin is in the first position, the protrusions 962 of the hub 950 are each disposed within one of the cutouts 943 of the base member 940 (i.e., a first protrusion is in a first cutout, and a second protrusion is in a second cutout). The hub 950 can then be rotated 180 degrees such that the protrusions 962 are moved out of the cutouts 943 of the base member 940 and at the end of the 180 degrees the protrusions 962 are moved into the other of the cutouts 943 of the base member 940 (i.e., the first protrusion is now in the second cutout, the second protrusion is now in the first cutout).


The base member 940 can also include cutout sections 966 and define side openings 967 (see, e.g., FIGS. 22 and 23) that can be used to couple a delivery device to the epicardial anchor device 900. For example, FIG. 31 illustrates a delivery device 948 having coupling arms 968 and coupling pins (not shown) extending inwardly from the arms 968. The side openings 967 can receive the coupling pins and the cutout sections 966 can be engaged by the coupling arms 968.


While various embodiments have been described above, it should be understood that they have been presented by way of example only, and not limitation. Where methods described above indicate certain events occurring in certain order, the ordering of certain events may be modified. Additionally, certain of the events may be performed concurrently in a parallel process when possible, as well as performed sequentially as described above


Where schematics and/or embodiments described above indicate certain components arranged in certain orientations or positions, the arrangement of components may be modified. While the embodiments have been particularly shown and described, it will be understood that various changes in form and details may be made. Any portion of the apparatus and/or methods described herein may be combined in any combination, except mutually exclusive combinations. The embodiments described herein can include various combinations and/or sub-combinations of the functions, components, and/or features of the different embodiments described.

Claims
  • 1. A method of securing a prosthetic heart valve to a heart, the method comprising: inserting a portion of a tether into a tether passageway defined by a tether attachment member, the tether extending from the prosthetic heart valve while the prosthetic heart valve is positioned within a native heart valve of the heart;disposing the tether attachment member adjacent an opening in a ventricular wall of the heart from which the tether extends; andactuating the tether attachment member such that a locking pin disposed within a locking pin channel defined by the tether attachment member intersects the tether passageway and engages a portion of the tether disposed within the tether passageway, securing the tether to the tether attachment member,wherein the tether attachment member includes a base member and a lever arm movably coupled to the base member, and actuating the tether attachment member includes moving the lever arm relative to the base member from a first position in which the tether can be inserted into the tether passageway to a second position in which the locking pin intersects the tether passageway and engages the portion of the tether.
  • 2. The method of claim 1, further comprising: prior to actuating the tether attachment member, adjusting the tension of the tether extending through the tether passageway to a desired tension.
  • 3. A method of securing a prosthetic heart valve to a heart, the method comprising: inserting a portion of a tether into a tether passageway defined by a tether attachment member, the tether extending from the prosthetic heart valve while the prosthetic heart valve is positioned within a native heart valve of the heart;disposing the tether attachment member adjacent an opening in a ventricular wall of the heart from which the tether extends; andactuating the tether attachment member such that a locking pin disposed within a locking pin channel defined by the tether attachment member intersects the tether passageway and engages a portion of the tether disposed within the tether passageway, securing the tether to the tether attachment member,wherein the tether attachment member includes a base member and a hub rotatably coupled to the base member, a portion of the locking pin being received within a locking pin channel defined by the hub, and actuating the tether attachment member includes rotating the hub relative to the base member such that the hub moves the locking pin linearly within the locking pin channel from a first position in which the locking pin is spaced from the tether passageway to a second position in which the locking pin intersects the tether passageway and engages the portion of the tether.
  • 4. The method of claim 3, wherein the base member has a retaining channel, and the hub has an outer perimeter portion received within the retaining channel.
  • 5. The method of claim 3, wherein the base member and the hub each define at least a portion of the tether passageway.
  • 6. The method of claim 3, wherein the locking pin channel intersects the tether passageway at a transverse angle and is in fluid communication therewith.
  • 7. The method of claim 3, wherein a bottom portion of the hub defines a curved channel in which a driver portion of the locking pin is received.
  • 8. The method of claim 7, wherein rotating the hub relative to the base member moves the driver portion of the locking pin along the curved channel.
  • 9. The method of claim 3, further comprising contacting the ventricular wall with a pad coupled to the tether attachment member so that the pad is disposed between the ventricular wall and the tether attachment member.
  • 10. The method of claim 3, wherein a tube member is coupled to the base member, the tube member defining a portion of the tether passageway.
  • 11. The method of claim 10, wherein a cover member is disposed over the tube member.
  • 12. The method of claim 3, wherein the base member defines a detent configured to receive therein a protrusion on the hub to limit the rotation of the hub relative to the base member.
  • 13. The method of claim 3, further comprising engaging coupling arms of a delivery device to cutout sections in the base member.
  • 14. The method of claim 13, further comprising engaging coupling pins extending from the coupling arms of the delivery device with side openings defined within the cutout sections of the base member.
  • 15. The method of claim 14, further comprising adjusting the tension of the tether using the delivery device while the delivery device is engaged to the base member.
  • 16. The method of claim 15, wherein actuating the tether attachment member is performed after adjusting the tension of the tether.
  • 17. The method of claim 3, further comprising: prior to actuating the tether attachment member, adjusting the tension of the tether extending through the tether passageway to a desired tension.
CROSS-REFERENCE TO RELATED APPLICATIONS

This application is a divisional of U.S. patent application Ser. No. 15/001,727, filed Jan. 20, 2016, which is continuation under 35 U.S.C. § 120 of International Application No. PCT/US2014/049218, filed Jul. 31, 2014, entitled “Epicardial Anchor Devices and Methods,” which claims priority to and the benefit of U.S. Provisional Patent Application No. 61/861,356, filed Aug. 1, 2013, entitled “Pursestring Epicardial Pad Device,” and U.S. Provisional Patent Application No. 61/895,975, filed Oct. 25, 2013, entitled “Improved Epicardial Pad Device,” each of the disclosures of which is incorporated herein by reference in its entirety. International Application No. PCT/US2014/049218 is also a continuation-in-part of U.S. patent application Ser. No. 14/224,764, filed Mar. 25, 2014, entitled “Pursestring Epicardial Pad Device,” which claims priority to and the benefit of U.S. Provisional Patent Application No. 61/861,356, filed Aug. 1, 2013, entitled “Pursestring Epicardial Pad Device,” each of the disclosures of which is incorporated herein by reference in its entirety.

US Referenced Citations (775)
Number Name Date Kind
2697008 Ross Dec 1954 A
3409013 Berry Nov 1968 A
3472230 Fogarty et al. Oct 1969 A
3476101 Ross Nov 1969 A
3548417 Kischer Dec 1970 A
3587115 Shiley Jun 1971 A
3657744 Ersek Apr 1972 A
3671979 Moulopoulos Jun 1972 A
3714671 Edwards et al. Feb 1973 A
3755823 Hancock Sep 1973 A
3976079 Samuels et al. Aug 1976 A
4003382 Dyke Jan 1977 A
4035849 Angell et al. Jul 1977 A
4056854 Boretos et al. Nov 1977 A
4073438 Meyer Feb 1978 A
4106129 Carpentier et al. Aug 1978 A
4222126 Boretos et al. Sep 1980 A
4265694 Boretos et al. May 1981 A
4297749 Davis et al. Nov 1981 A
4339831 Johnson Jul 1982 A
4343048 Ross et al. Aug 1982 A
4345340 Rosen Aug 1982 A
4373216 Klawitter Feb 1983 A
4406022 Roy Sep 1983 A
4470157 Love Sep 1984 A
4490859 Black et al. Jan 1985 A
4535483 Klawitter et al. Aug 1985 A
4574803 Storz Mar 1986 A
4585705 Broderick et al. Apr 1986 A
4592340 Boyles Jun 1986 A
4605407 Black et al. Aug 1986 A
4612011 Kautzky Sep 1986 A
4626255 Reichart et al. Dec 1986 A
4638886 Marietta Jan 1987 A
4643732 Pietsch et al. Feb 1987 A
4655771 Wallsten Apr 1987 A
4692164 Dzemeshkevich et al. Sep 1987 A
4733665 Palmaz Mar 1988 A
4759758 Gabbay Jul 1988 A
4762128 Rosenbluth Aug 1988 A
4777951 Cribier et al. Oct 1988 A
4787899 Lazarus Nov 1988 A
4787901 Baykut Nov 1988 A
4796629 Grayzel Jan 1989 A
4824180 Levrai Apr 1989 A
4829990 Thuroff et al. May 1989 A
4830117 Capasso May 1989 A
4851001 Taheri Jul 1989 A
4856516 Hillstead Aug 1989 A
4858810 Intlekofer et al. Aug 1989 A
4878495 Grayzel Nov 1989 A
4878906 Lindemann et al. Nov 1989 A
4883458 Shiber Nov 1989 A
4922905 Strecker May 1990 A
4923013 De Gennaro May 1990 A
4960424 Grooters Oct 1990 A
4966604 Reiss Oct 1990 A
4979939 Shiber Dec 1990 A
4986830 Owens et al. Jan 1991 A
4994077 Dobben Feb 1991 A
4996873 Takeuchi Mar 1991 A
5007896 Shiber Apr 1991 A
5026366 Leckrone Jun 1991 A
5032128 Alonso Jul 1991 A
5035706 Giantureo et al. Jul 1991 A
5037434 Lane Aug 1991 A
5047041 Samuels Sep 1991 A
5059177 Towne et al. Oct 1991 A
5064435 Porter Nov 1991 A
5080668 Bolz et al. Jan 1992 A
5085635 Cragg Feb 1992 A
5089015 Ross Feb 1992 A
5152771 Sabbaghian et al. Oct 1992 A
5163953 Vince Nov 1992 A
5167628 Boyles Dec 1992 A
5192297 Hull Mar 1993 A
5201880 Wright et al. Apr 1993 A
5266073 Wall Nov 1993 A
5282847 Trescony et al. Feb 1994 A
5295958 Shturman Mar 1994 A
5306296 Wright et al. Apr 1994 A
5332402 Teitelbaum Jul 1994 A
5336616 Livesey et al. Aug 1994 A
5344442 Deac Sep 1994 A
5360444 Kusuhara Nov 1994 A
5364407 Poll Nov 1994 A
5370685 Stevens Dec 1994 A
5397351 Pavcnik et al. Mar 1995 A
5411055 Kane May 1995 A
5411552 Andersen et al. May 1995 A
5415667 Frater May 1995 A
5443446 Shturman Aug 1995 A
5480424 Cox Jan 1996 A
5500014 Quijano et al. Mar 1996 A
5545209 Roberts et al. Aug 1996 A
5545214 Stevens Aug 1996 A
5549665 Vesely et al. Aug 1996 A
5554184 Machiraju Sep 1996 A
5554185 Block et al. Sep 1996 A
5571175 Vanney et al. Nov 1996 A
5578076 Krueger et al. Nov 1996 A
5591185 Kilmer et al. Jan 1997 A
5607462 Imran Mar 1997 A
5607464 Trescony et al. Mar 1997 A
5609626 Quijano et al. Mar 1997 A
5639274 Fischell et al. Jun 1997 A
5662704 Gross Sep 1997 A
5665115 Cragg Sep 1997 A
5674279 Wright et al. Oct 1997 A
5697905 d'Ambrosio Dec 1997 A
5702368 Stevens et al. Dec 1997 A
5716417 Girard et al. Feb 1998 A
5728068 Leone et al. Mar 1998 A
5728151 Garrison et al. Mar 1998 A
5735842 Krueger et al. Apr 1998 A
5741333 Frid Apr 1998 A
5749890 Shaknovich May 1998 A
5756476 Epstein et al. May 1998 A
5769812 Stevens et al. Jun 1998 A
5792179 Sideris Aug 1998 A
5800508 Goicoechea et al. Sep 1998 A
5833673 Ockuly et al. Nov 1998 A
5840081 Andersen et al. Nov 1998 A
5855597 Jayaraman Jan 1999 A
5855601 Bessler et al. Jan 1999 A
5855602 Angell Jan 1999 A
5904697 Gifford, III et al. May 1999 A
5925063 Khosravi Jul 1999 A
5957949 Leonhardt et al. Sep 1999 A
5968052 Sullivan, III et al. Oct 1999 A
5968068 Dehdashtian et al. Oct 1999 A
5972030 Garrison et al. Oct 1999 A
5993481 Marcade et al. Nov 1999 A
6027525 Suh et al. Feb 2000 A
6042607 Williamson, IV et al. Mar 2000 A
6045497 Schweich, Jr. et al. Apr 2000 A
6063112 Sgro May 2000 A
6077214 Mortier et al. Jun 2000 A
6099508 Bousquet Aug 2000 A
6132473 Williams et al. Oct 2000 A
6168614 Andersen et al. Jan 2001 B1
6171335 Wheatley et al. Jan 2001 B1
6174327 Mertens et al. Jan 2001 B1
6183411 Mortier et al. Feb 2001 B1
6210408 Chandrasekaran et al. Apr 2001 B1
6217585 Houser et al. Apr 2001 B1
6221091 Khosravi Apr 2001 B1
6231602 Carpentier et al. May 2001 B1
6245102 Jayaraman Jun 2001 B1
6260552 Mortier et al. Jul 2001 B1
6261222 Schweich, Jr. et al. Jul 2001 B1
6264602 Mortier et al. Jul 2001 B1
6287339 Vazquez et al. Sep 2001 B1
6299637 Shaolian et al. Oct 2001 B1
6302906 Goicoechea et al. Oct 2001 B1
6312465 Griffin et al. Nov 2001 B1
6332893 Mortier et al. Dec 2001 B1
6350277 Kocur Feb 2002 B1
6358277 Duran Mar 2002 B1
6379372 Dehdashtian et al. Apr 2002 B1
6402679 Mortier et al. Jun 2002 B1
6402680 Mortier et al. Jun 2002 B2
6402781 Langberg et al. Jun 2002 B1
6406420 McCarthy et al. Jun 2002 B1
6425916 Garrison et al. Jul 2002 B1
6440164 DiMatteo et al. Aug 2002 B1
6454799 Schreck Sep 2002 B1
6458153 Bailey et al. Oct 2002 B1
6461382 Cao Oct 2002 B1
6468660 Ogle et al. Oct 2002 B2
6482228 Norred Nov 2002 B1
6488704 Connelly et al. Dec 2002 B1
6537198 Vidlund et al. Mar 2003 B1
6540782 Snyders Apr 2003 B1
6569196 Vesely May 2003 B1
6575252 Reed Jun 2003 B2
6582462 Andersen et al. Jun 2003 B1
6605112 Moll et al. Aug 2003 B1
6616684 Vidlund et al. Sep 2003 B1
6622730 Ekvall et al. Sep 2003 B2
6629534 St. Goar et al. Oct 2003 B1
6629921 Schweich, Jr. et al. Oct 2003 B1
6648077 Hoffman Nov 2003 B2
6648921 Anderson et al. Nov 2003 B2
6652578 Bailey et al. Nov 2003 B2
6669724 Park et al. Dec 2003 B2
6706065 Langberg et al. Mar 2004 B2
6709456 Langberg et al. Mar 2004 B2
6723038 Schroeder et al. Apr 2004 B1
6726715 Sutherland Apr 2004 B2
6730118 Spenser et al. May 2004 B2
6733525 Yang et al. May 2004 B2
6740105 Yodat et al. May 2004 B2
6746401 Panescu Jun 2004 B2
6746471 Mortier et al. Jun 2004 B2
6752813 Goldfarb et al. Jun 2004 B2
6764510 Vidlund et al. Jul 2004 B2
6797002 Spence et al. Sep 2004 B2
6810882 Langberg et al. Nov 2004 B2
6830584 Seguin Dec 2004 B1
6854668 Wancho et al. Feb 2005 B2
6855144 Lesh Feb 2005 B2
6858001 Aboul-Hosn Feb 2005 B1
6890353 Cohn et al. May 2005 B2
6893460 Spenser et al. May 2005 B2
6896690 Lambrecht et al. May 2005 B1
6908424 Mortier et al. Jun 2005 B2
6908481 Cribier Jun 2005 B2
6936067 Buchanan Aug 2005 B2
6945996 Sedransk Sep 2005 B2
6955175 Stevens et al. Oct 2005 B2
6974476 McGuckin, Jr. et al. Dec 2005 B2
6976543 Fischer Dec 2005 B1
6997950 Chawla Feb 2006 B2
7018406 Seguin et al. Mar 2006 B2
7018408 Bailey et al. Mar 2006 B2
7044905 Vidlund et al. May 2006 B2
7060021 Wilk Jun 2006 B1
7077862 Vidlund et al. Jul 2006 B2
7087064 Hyde Aug 2006 B1
7100614 Stevens et al. Sep 2006 B2
7101395 Tremulis et al. Sep 2006 B2
7108717 Freidberg Sep 2006 B2
7112219 Vidlund et al. Sep 2006 B2
7115141 Menz et al. Oct 2006 B2
7141064 Scott et al. Nov 2006 B2
7175656 Khairkhahan Feb 2007 B2
7198646 Figulla et al. Apr 2007 B2
7201772 Schwammenthal et al. Apr 2007 B2
7247134 Vidlund et al. Jul 2007 B2
7252682 Seguin Aug 2007 B2
7267686 DiMatteo et al. Sep 2007 B2
7275604 Wall Oct 2007 B1
7276078 Spenser et al. Oct 2007 B2
7276084 Yang et al. Oct 2007 B2
7316706 Bloom et al. Jan 2008 B2
7318278 Zhang et al. Jan 2008 B2
7326236 Andreas et al. Feb 2008 B2
7329278 Seguin et al. Feb 2008 B2
7331991 Kheradvar et al. Feb 2008 B2
7335213 Hyde et al. Feb 2008 B1
7374571 Pease et al. May 2008 B2
7377941 Rhee et al. May 2008 B2
7381210 Zarbatany et al. Jun 2008 B2
7381218 Schreck Jun 2008 B2
7393360 Spenser et al. Jul 2008 B2
7404824 Webler et al. Jul 2008 B1
7416554 Lam et al. Aug 2008 B2
7422072 Dade Sep 2008 B2
7429269 Schwammenthal et al. Sep 2008 B2
7442204 Schwammenthal et al. Oct 2008 B2
7445631 Salahieh et al. Nov 2008 B2
7462191 Spenser et al. Dec 2008 B2
7470285 Nugent et al. Dec 2008 B2
7500989 Solem et al. Mar 2009 B2
7503931 Kowalsky et al. Mar 2009 B2
7510572 Gabbay Mar 2009 B2
7510575 Spenser et al. Mar 2009 B2
7513908 Lattouf Apr 2009 B2
7524330 Berreklouw Apr 2009 B2
7527647 Spence May 2009 B2
7534260 Lattouf May 2009 B2
7556646 Yang et al. Jul 2009 B2
7579381 Dove Aug 2009 B2
7585321 Cribier Sep 2009 B2
7591847 Navia et al. Sep 2009 B2
7618446 Andersen et al. Nov 2009 B2
7618447 Case et al. Nov 2009 B2
7621948 Herrmann et al. Nov 2009 B2
7632304 Park Dec 2009 B2
7632308 Loulmet Dec 2009 B2
7635386 Gammie Dec 2009 B1
7674222 Nikolic et al. Mar 2010 B2
7674286 Alfieri et al. Mar 2010 B2
7695510 Bloom et al. Apr 2010 B2
7708775 Rowe et al. May 2010 B2
7748389 Salahieh et al. Jul 2010 B2
7766961 Patel et al. Aug 2010 B2
7789909 Andersen et al. Sep 2010 B2
7803168 Gifford et al. Sep 2010 B2
7803184 McGuckin, Jr. et al. Sep 2010 B2
7803185 Gabbay Sep 2010 B2
7806928 Rowe et al. Oct 2010 B2
7837727 Goetz et al. Nov 2010 B2
7854762 Speziali et al. Dec 2010 B2
7892281 Seguin et al. Feb 2011 B2
7896915 Guyenot et al. Mar 2011 B2
7901454 Kapadia et al. Mar 2011 B2
7927370 Webler et al. Apr 2011 B2
7931630 Nishtala et al. Apr 2011 B2
7942928 Webler et al. May 2011 B2
7955247 Levine et al. Jun 2011 B2
7955385 Crittenden Jun 2011 B2
7972378 Tabor et al. Jul 2011 B2
3007992 Tian et al. Aug 2011 A1
7988727 Santamore et al. Aug 2011 B2
7993394 Hariton et al. Aug 2011 B2
8029556 Rowe Oct 2011 B2
8043368 Crabtree Oct 2011 B2
8052749 Salahieh et al. Nov 2011 B2
8052750 Tuval et al. Nov 2011 B2
8052751 Aklog et al. Nov 2011 B2
8062355 Figulla et al. Nov 2011 B2
8062359 Marquez et al. Nov 2011 B2
8070802 Lamphere et al. Dec 2011 B2
8109996 Stacchino et al. Feb 2012 B2
8142495 Hasenkam et al. Mar 2012 B2
8152821 Gambale et al. Apr 2012 B2
8157810 Case et al. Apr 2012 B2
8167932 Bourang et al. May 2012 B2
8167934 Styrc et al. May 2012 B2
8187299 Goldfarb et al. May 2012 B2
8206439 Gomez Duran Jun 2012 B2
8216301 Bonhoeffer et al. Jul 2012 B2
8226711 Mortier et al. Jul 2012 B2
8236045 Benichou et al. Aug 2012 B2
8241274 Keogh et al. Aug 2012 B2
8252051 Chau et al. Aug 2012 B2
8303653 Bonhoeffer et al. Nov 2012 B2
8308796 Lashinski et al. Nov 2012 B2
8323334 Deem et al. Dec 2012 B2
8353955 Styrc et al. Jan 2013 B2
RE44075 Williamson et al. Mar 2013 E
8449599 Chau et al. May 2013 B2
8454656 Tuval Jun 2013 B2
8470028 Thornton et al. Jun 2013 B2
8480730 Maurer et al. Jul 2013 B2
8486138 Vesely Jul 2013 B2
8506623 Wilson et al. Aug 2013 B2
8506624 Vidlund et al. Aug 2013 B2
8578705 Sindano et al. Nov 2013 B2
8579913 Nielsen Nov 2013 B2
8591573 Barone Nov 2013 B2
8591576 Hasenkam et al. Nov 2013 B2
8597347 Maurer et al. Dec 2013 B2
8685086 Navia et al. Apr 2014 B2
8790394 Miller et al. Jul 2014 B2
8845717 Khairkhahan et al. Sep 2014 B2
8888843 Khairkhahan et al. Nov 2014 B2
8900214 Nance et al. Dec 2014 B2
8900295 Migliazza et al. Dec 2014 B2
8926696 Cabiri et al. Jan 2015 B2
8932342 McHugo et al. Jan 2015 B2
8932348 Solem et al. Jan 2015 B2
8945208 Jimenez et al. Feb 2015 B2
8956407 Macoviak et al. Feb 2015 B2
8979922 Jayasinghe et al. Mar 2015 B2
8986376 Solem Mar 2015 B2
9011522 Annest Apr 2015 B2
9023099 Duffy et al. May 2015 B2
9034032 McLean et al. May 2015 B2
9034033 McLean et al. May 2015 B2
9039757 McLean et al. May 2015 B2
9039759 Alkhatib et al. May 2015 B2
9078645 Conklin et al. Jul 2015 B2
9078749 Lutter et al. Jul 2015 B2
9084676 Chau et al. Jul 2015 B2
9095433 Lutter et al. Aug 2015 B2
9125742 Yoganathan et al. Sep 2015 B2
9149357 Seguin Oct 2015 B2
9161837 Kapadia Oct 2015 B2
9168137 Subramanian et al. Oct 2015 B2
9232995 Kovalsky et al. Jan 2016 B2
9232998 Wilson et al. Jan 2016 B2
9232999 Maurer et al. Jan 2016 B2
9241702 Maisano et al. Jan 2016 B2
9254192 Lutter et al. Feb 2016 B2
9265608 Miller et al. Feb 2016 B2
9289295 Aklog et al. Mar 2016 B2
9289297 Wilson et al. Mar 2016 B2
9345573 Nyuli et al. May 2016 B2
9480557 Pellegrini et al. Nov 2016 B2
9480559 Vidlund et al. Nov 2016 B2
9526611 Tegels et al. Dec 2016 B2
9597181 Christianson et al. Mar 2017 B2
9610159 Christianson et al. Apr 2017 B2
9625003 Hooti et al. Apr 2017 B2
9675454 Vidlund et al. Jun 2017 B2
9730792 Lutter et al. Aug 2017 B2
9827092 Vidlund et al. Nov 2017 B2
9833315 Vidlund et al. Dec 2017 B2
9867700 Bakis et al. Jan 2018 B2
9883941 Hastings et al. Feb 2018 B2
9895221 Vidlund Feb 2018 B2
9986993 Vidlund et al. Jun 2018 B2
20010018611 Solem et al. Aug 2001 A1
20010021872 Bailey et al. Sep 2001 A1
20010025171 Mortier et al. Sep 2001 A1
20020010427 Scarfone et al. Jan 2002 A1
20020116054 Lundell et al. Aug 2002 A1
20020139056 Finnell Oct 2002 A1
20020151961 Lashinski et al. Oct 2002 A1
20020161377 Rabkin Oct 2002 A1
20020173842 Buchanan Nov 2002 A1
20020183827 Derus et al. Dec 2002 A1
20030010509 Hoffman Jan 2003 A1
20030036698 Kohler et al. Feb 2003 A1
20030050694 Yang et al. Mar 2003 A1
20030078652 Sutherland Apr 2003 A1
20030100939 Yodfat et al. May 2003 A1
20030105519 Fasol et al. Jun 2003 A1
20030105520 Alferness et al. Jun 2003 A1
20030120340 Liska et al. Jun 2003 A1
20030130731 Vidlund et al. Jul 2003 A1
20030149476 Damm et al. Aug 2003 A1
20030212454 Scott et al. Nov 2003 A1
20040039436 Spenser et al. Feb 2004 A1
20040049266 Anduiza et al. Mar 2004 A1
20040064014 Melvin et al. Apr 2004 A1
20040092858 Wilson et al. May 2004 A1
20040093075 Kuehne May 2004 A1
20040097865 Anderson et al. May 2004 A1
20040127983 Mortier et al. Jul 2004 A1
20040133263 Dusbabek et al. Jul 2004 A1
20040147958 Lam et al. Jul 2004 A1
20040152947 Schroeder et al. Aug 2004 A1
20040162610 Liska et al. Aug 2004 A1
20040163828 Silverstein et al. Aug 2004 A1
20040181239 Dorn et al. Sep 2004 A1
20040186565 Schreck Sep 2004 A1
20040186566 Hindrichs et al. Sep 2004 A1
20040260317 Bloom et al. Dec 2004 A1
20040260389 Case et al. Dec 2004 A1
20050004652 van der Burg et al. Jan 2005 A1
20050004666 Altieri et al. Jan 2005 A1
20050075727 Wheatley Apr 2005 A1
20050080402 Santamore et al. Apr 2005 A1
20050085900 Case et al. Apr 2005 A1
20050096498 Houser et al. May 2005 A1
20050107661 Lau et al. May 2005 A1
20050113798 Slater et al. May 2005 A1
20050113810 Houser et al. May 2005 A1
20050113811 Houser et al. May 2005 A1
20050119519 Girard et al. Jun 2005 A9
20050121206 Dolan Jun 2005 A1
20050125012 Houser et al. Jun 2005 A1
20050137686 Salahieh et al. Jun 2005 A1
20050137688 Salahieh et al. Jun 2005 A1
20050137695 Salahieh et al. Jun 2005 A1
20050137698 Salahieh et al. Jun 2005 A1
20050148815 Mortier et al. Jul 2005 A1
20050177180 Kaganov et al. Aug 2005 A1
20050197695 Stacchino et al. Sep 2005 A1
20050203614 Forster et al. Sep 2005 A1
20050203615 Forster et al. Sep 2005 A1
20050203617 Forster et al. Sep 2005 A1
20050234546 Nugent et al. Oct 2005 A1
20050240200 Bergheim Oct 2005 A1
20050251209 Saadat et al. Nov 2005 A1
20050256567 Lim et al. Nov 2005 A1
20050283231 Haug et al. Dec 2005 A1
20050288766 Plain et al. Dec 2005 A1
20060004442 Spenser et al. Jan 2006 A1
20060025784 Starksen et al. Feb 2006 A1
20060025857 Bergheim et al. Feb 2006 A1
20060030885 Hyde Feb 2006 A1
20060042803 Gallaher Mar 2006 A1
20060047338 Jenson et al. Mar 2006 A1
20060052868 Mortier et al. Mar 2006 A1
20060058872 Salahieh et al. Mar 2006 A1
20060094983 Burbank et al. May 2006 A1
20060129025 Levine et al. Jun 2006 A1
20060142784 Kontos Jun 2006 A1
20060161040 McCarthy et al. Jul 2006 A1
20060161249 Realyvasquez et al. Jul 2006 A1
20060167541 Lattouf Jul 2006 A1
20060195134 Crittenden Aug 2006 A1
20060195183 Navia et al. Aug 2006 A1
20060229708 Powell et al. Oct 2006 A1
20060229719 Marquez et al. Oct 2006 A1
20060241745 Solem Oct 2006 A1
20060247491 Vidlund et al. Nov 2006 A1
20060252984 Rahdert et al. Nov 2006 A1
20060259135 Navia et al. Nov 2006 A1
20060259136 Nguyen et al. Nov 2006 A1
20060259137 Artof et al. Nov 2006 A1
20060276874 Wilson et al. Dec 2006 A1
20060282161 Huynh et al. Dec 2006 A1
20060287716 Banbury et al. Dec 2006 A1
20060287717 Rowe et al. Dec 2006 A1
20070005131 Taylor Jan 2007 A1
20070005231 Seguchi Jan 2007 A1
20070010877 Salahieh et al. Jan 2007 A1
20070016286 Herrmann et al. Jan 2007 A1
20070016288 Gurskis et al. Jan 2007 A1
20070027535 Purdy et al. Feb 2007 A1
20070038291 Case et al. Feb 2007 A1
20070050020 Spence Mar 2007 A1
20070061010 Hauser et al. Mar 2007 A1
20070066863 Rafiee et al. Mar 2007 A1
20070073387 Forster et al. Mar 2007 A1
20070078297 Rafiee et al. Apr 2007 A1
20070083076 Lichtenstein Apr 2007 A1
20070083259 Bloom et al. Apr 2007 A1
20070093890 Eliasen et al. Apr 2007 A1
20070100439 Cangialosi et al. May 2007 A1
20070112422 Dehdashtian May 2007 A1
20070112425 Schaller et al. May 2007 A1
20070118151 Davidson May 2007 A1
20070118154 Crabtree May 2007 A1
20070118210 Pinchuk May 2007 A1
20070118213 Loulmet May 2007 A1
20070142906 Figulla et al. Jun 2007 A1
20070161846 Nikolic et al. Jul 2007 A1
20070162048 Quinn et al. Jul 2007 A1
20070162103 Case et al. Jul 2007 A1
20070168024 Khairkhahan Jul 2007 A1
20070185565 Schwammenthal et al. Aug 2007 A1
20070185571 Kapadia et al. Aug 2007 A1
20070203575 Forster et al. Aug 2007 A1
20070213813 Von Segesser et al. Sep 2007 A1
20070215362 Rodgers Sep 2007 A1
20070221388 Johnson Sep 2007 A1
20070233239 Navia et al. Oct 2007 A1
20070239265 Birdsall Oct 2007 A1
20070256843 Pahila Nov 2007 A1
20070265658 Nelson et al. Nov 2007 A1
20070267202 Mariller Nov 2007 A1
20070270932 Headley et al. Nov 2007 A1
20070270943 Solem et al. Nov 2007 A1
20070293944 Spenser et al. Dec 2007 A1
20080009940 Cribier Jan 2008 A1
20080033543 Gurskis et al. Feb 2008 A1
20080065011 Marchand et al. Mar 2008 A1
20080071361 Tuval et al. Mar 2008 A1
20080071362 Tuval et al. Mar 2008 A1
20080071363 Tuval et al. Mar 2008 A1
20080071366 Tuval et al. Mar 2008 A1
20080071368 Tuval et al. Mar 2008 A1
20080071369 Tuval et al. Mar 2008 A1
20080082163 Woo Apr 2008 A1
20080082166 Styrc et al. Apr 2008 A1
20080091264 Machold et al. Apr 2008 A1
20080114442 Mitchell et al. May 2008 A1
20080125861 Webler et al. May 2008 A1
20080147179 Cai et al. Jun 2008 A1
20080154355 Benichou et al. Jun 2008 A1
20080154356 Obermiller et al. Jun 2008 A1
20080161911 Revuelta et al. Jul 2008 A1
20080172035 Starksen et al. Jul 2008 A1
20080177381 Navia et al. Jul 2008 A1
20080183203 Fitzgerald et al. Jul 2008 A1
20080183273 Mesana et al. Jul 2008 A1
20080188928 Salahieh et al. Aug 2008 A1
20080208328 Antocci et al. Aug 2008 A1
20080208332 Lamphere et al. Aug 2008 A1
20080221672 Lamphere et al. Sep 2008 A1
20080243150 Starksen et al. Oct 2008 A1
20080243245 Thambar et al. Oct 2008 A1
20080255660 Guyenot et al. Oct 2008 A1
20080255661 Straubinger et al. Oct 2008 A1
20080281411 Berreklouw Nov 2008 A1
20080288060 Kaye et al. Nov 2008 A1
20080293996 Evans et al. Nov 2008 A1
20090005863 Goetz et al. Jan 2009 A1
20090048668 Wilson et al. Feb 2009 A1
20090054968 Bonhoeffer et al. Feb 2009 A1
20090054974 McGuckin, Jr. et al. Feb 2009 A1
20090062908 Bonhoeffer et al. Mar 2009 A1
20090076598 Salahieh et al. Mar 2009 A1
20090082619 De Marchena Mar 2009 A1
20090088836 Bishop et al. Apr 2009 A1
20090099410 De Marchena Apr 2009 A1
20090112309 Jaramillo et al. Apr 2009 A1
20090131849 Maurer et al. May 2009 A1
20090132035 Roth et al. May 2009 A1
20090137861 Goldberg et al. May 2009 A1
20090138079 Tuval et al. May 2009 A1
20090157175 Benichou Jun 2009 A1
20090164005 Dove et al. Jun 2009 A1
20090171432 Von Segesser et al. Jul 2009 A1
20090171447 Von Segesser et al. Jul 2009 A1
20090171456 Kveen et al. Jul 2009 A1
20090177266 Powell et al. Jul 2009 A1
20090192601 Rafiee et al. Jul 2009 A1
20090210052 Forster et al. Aug 2009 A1
20090216322 Le et al. Aug 2009 A1
20090222076 Figulla et al. Sep 2009 A1
20090224529 Gill Sep 2009 A1
20090234318 Loulmet et al. Sep 2009 A1
20090234435 Johnson et al. Sep 2009 A1
20090234443 Ottma et al. Sep 2009 A1
20090240320 Tuval et al. Sep 2009 A1
20090248149 Gabbay Oct 2009 A1
20090276040 Rowe et al. Nov 2009 A1
20090281619 Le et al. Nov 2009 A1
20090287299 Tabor et al. Nov 2009 A1
20090292262 Adams et al. Nov 2009 A1
20090319037 Rowe et al. Dec 2009 A1
20090326575 Galdonik et al. Dec 2009 A1
20100016958 St. Goar et al. Jan 2010 A1
20100021382 Dorshow et al. Jan 2010 A1
20100023117 Yoganathan et al. Jan 2010 A1
20100036479 Hill et al. Feb 2010 A1
20100049313 Alon et al. Feb 2010 A1
20100082094 Quadri et al. Apr 2010 A1
20100161041 Maisano et al. Jun 2010 A1
20100168839 Braido et al. Jul 2010 A1
20100179641 Ryan et al. Jul 2010 A1
20100185277 Braido et al. Jul 2010 A1
20100185278 Schankereli Jul 2010 A1
20100191326 Alkhatib Jul 2010 A1
20100192402 Yamaguchi et al. Aug 2010 A1
20100204781 Alkhatib Aug 2010 A1
20100210899 Schankereli Aug 2010 A1
20100217382 Chau et al. Aug 2010 A1
20100249489 Jarvik Sep 2010 A1
20100249923 Alkhatib et al. Sep 2010 A1
20100280604 Zipory et al. Nov 2010 A1
20100286768 Alkhatib Nov 2010 A1
20100298755 McNamara et al. Nov 2010 A1
20100298931 Quadri et al. Nov 2010 A1
20110004296 Lutter et al. Jan 2011 A1
20110015616 Straubinger et al. Jan 2011 A1
20110015728 Jimenez et al. Jan 2011 A1
20110015729 Jimenez et al. Jan 2011 A1
20110029072 Gabbay Feb 2011 A1
20110066231 Cartledge et al. Mar 2011 A1
20110066233 Thornton et al. Mar 2011 A1
20110112632 Chau et al. May 2011 A1
20110137397 Chau et al. Jun 2011 A1
20110137408 Bergheim Jun 2011 A1
20110224655 Asirvatham et al. Sep 2011 A1
20110224678 Gabbay Sep 2011 A1
20110224728 Martin et al. Sep 2011 A1
20110224784 Quinn Sep 2011 A1
20110245911 Quill et al. Oct 2011 A1
20110251682 Murray, III et al. Oct 2011 A1
20110264191 Rothstein Oct 2011 A1
20110264206 Tabor Oct 2011 A1
20110288637 De Marchena Nov 2011 A1
20110319988 Schankereli et al. Dec 2011 A1
20110319989 Lane et al. Dec 2011 A1
20120010694 Lutter et al. Jan 2012 A1
20120016468 Robin et al. Jan 2012 A1
20120022640 Gross et al. Jan 2012 A1
20120035703 Lutter et al. Feb 2012 A1
20120035713 Lutter et al. Feb 2012 A1
20120035722 Tuval Feb 2012 A1
20120053686 McNamara et al. Mar 2012 A1
20120059487 Cunanan et al. Mar 2012 A1
20120089171 Hastings et al. Apr 2012 A1
20120101571 Thambar et al. Apr 2012 A1
20120101572 Kovalsky et al. Apr 2012 A1
20120116351 Chomas et al. May 2012 A1
20120123529 Levi et al. May 2012 A1
20120158129 Duffy et al. Jun 2012 A1
20120165930 Gifford, III et al. Jun 2012 A1
20120179244 Schankereli et al. Jul 2012 A1
20120203336 Annest Aug 2012 A1
20120215303 Quadri et al. Aug 2012 A1
20120226348 Lane et al. Sep 2012 A1
20120283824 Lutter et al. Nov 2012 A1
20120289945 Segermark Nov 2012 A1
20130030522 Rowe Jan 2013 A1
20130053950 Rowe et al. Feb 2013 A1
20130066341 Ketai et al. Mar 2013 A1
20130079873 Migliazza et al. Mar 2013 A1
20130131788 Quadri et al. May 2013 A1
20130158600 Conklin et al. Jun 2013 A1
20130172978 Vidlund et al. Jul 2013 A1
20130184811 Rowe et al. Jul 2013 A1
20130190860 Sundt, III Jul 2013 A1
20130190861 Chau et al. Jul 2013 A1
20130197622 Mitra et al. Aug 2013 A1
20130226288 Goldwasser et al. Aug 2013 A1
20130231735 Deem et al. Sep 2013 A1
20130274874 Hammer Oct 2013 A1
20130282101 Eidenschink et al. Oct 2013 A1
20130310928 Morriss et al. Nov 2013 A1
20130317603 McLean et al. Nov 2013 A1
20130325041 Annest et al. Dec 2013 A1
20130325110 Khalil et al. Dec 2013 A1
20130338752 Geusen et al. Dec 2013 A1
20140046433 Kovalsky Feb 2014 A1
20140081323 Hawkins Mar 2014 A1
20140094918 Vishnubholta et al. Apr 2014 A1
20140142691 Pouletty May 2014 A1
20140163668 Rafiee Jun 2014 A1
20140194981 Menk et al. Jul 2014 A1
20140194983 Kovalsky et al. Jul 2014 A1
20140214159 Vidlund et al. Jul 2014 A1
20140222142 Kovalsky et al. Aug 2014 A1
20140243966 Garde et al. Aug 2014 A1
20140277419 Garde et al. Sep 2014 A1
20140296969 Tegels et al. Oct 2014 A1
20140296970 Ekvall et al. Oct 2014 A1
20140296971 Tegels et al. Oct 2014 A1
20140296972 Tegels et al. Oct 2014 A1
20140296975 Tegels et al. Oct 2014 A1
20140303718 Tegels et al. Oct 2014 A1
20140309732 Solem Oct 2014 A1
20140316516 Vidlund et al. Oct 2014 A1
20140324160 Benichou et al. Oct 2014 A1
20140324161 Tegels et al. Oct 2014 A1
20140324164 Gross et al. Oct 2014 A1
20140331475 Duffy et al. Nov 2014 A1
20140358224 Tegels et al. Dec 2014 A1
20140364942 Straubinger et al. Dec 2014 A1
20140364944 Lutter et al. Dec 2014 A1
20140379076 Vidlund et al. Dec 2014 A1
20150005874 Vidlund et al. Jan 2015 A1
20150011821 Gorman et al. Jan 2015 A1
20150025553 Del Nido et al. Jan 2015 A1
20150057705 Vidlund Feb 2015 A1
20150073542 Heldman Mar 2015 A1
20150073545 Braido Mar 2015 A1
20150094802 Buchbinder et al. Apr 2015 A1
20150105856 Rowe et al. Apr 2015 A1
20150119936 Gilmore et al. Apr 2015 A1
20150119978 Tegels et al. Apr 2015 A1
20150127093 Hosmer et al. May 2015 A1
20150127096 Rowe et al. May 2015 A1
20150134050 Solem et al. May 2015 A1
20150142100 Morriss et al. May 2015 A1
20150142101 Coleman et al. May 2015 A1
20150142103 Vidlund May 2015 A1
20150142104 Braido May 2015 A1
20150173897 Raanani et al. Jun 2015 A1
20150196393 Vidlund et al. Jul 2015 A1
20150196688 James Jul 2015 A1
20150202044 Chau et al. Jul 2015 A1
20150216653 Freudenthal Aug 2015 A1
20150216660 Pintor Aug 2015 A1
20150223820 Olson Aug 2015 A1
20150223934 Vidlund et al. Aug 2015 A1
20150238312 Lashinski Aug 2015 A1
20150238729 Jenson et al. Aug 2015 A1
20150272731 Racchini et al. Oct 2015 A1
20150305860 Wang et al. Oct 2015 A1
20150305864 Quadri et al. Oct 2015 A1
20150305868 Lutter et al. Oct 2015 A1
20150327995 Morin et al. Nov 2015 A1
20150328001 McLean Nov 2015 A1
20150335424 McLean Nov 2015 A1
20150335429 Morriss et al. Nov 2015 A1
20150342717 O'Donnell et al. Dec 2015 A1
20150351903 Morriss et al. Dec 2015 A1
20150351906 Hammer et al. Dec 2015 A1
20160000562 Siegel Jan 2016 A1
20160008131 Christianson et al. Jan 2016 A1
20160067042 Murad et al. Mar 2016 A1
20160074160 Christianson et al. Mar 2016 A1
20160106537 Christianson et al. Apr 2016 A1
20160113764 Sheahan Apr 2016 A1
20160151155 Lutter et al. Jun 2016 A1
20160206280 Vidlund et al. Jul 2016 A1
20160242902 Morriss Aug 2016 A1
20160262879 Meiri et al. Sep 2016 A1
20160262881 Schankereli et al. Sep 2016 A1
20160278955 Liu et al. Sep 2016 A1
20160317290 Chau Nov 2016 A1
20160324635 Vidlund et al. Nov 2016 A1
20160331527 Vidlund et al. Nov 2016 A1
20160346086 Solem Dec 2016 A1
20160367365 Conklin Dec 2016 A1
20160367367 Maisano et al. Dec 2016 A1
20160367368 Vidlund et al. Dec 2016 A1
20170079790 Vidlund et al. Mar 2017 A1
20170100248 Tegels et al. Apr 2017 A1
20170128208 Christianson et al. May 2017 A1
20170181854 Christianson et al. Jun 2017 A1
20170196688 Christianson et al. Jul 2017 A1
20170252153 Chau et al. Sep 2017 A1
20170266001 Vidlund et al. Sep 2017 A1
20170281343 Christianson et al. Oct 2017 A1
20170312076 Lutter et al. Nov 2017 A1
20170312077 Vidlund et al. Nov 2017 A1
20170319333 Tegels et al. Nov 2017 A1
20180028314 Ekvall et al. Feb 2018 A1
20180078368 Vidlund et al. Mar 2018 A1
20180078370 Kovalsky et al. Mar 2018 A1
20180147055 Vidlund et al. May 2018 A1
20180193138 Vidlund Jul 2018 A1
20180263618 Vidlund et al. Sep 2018 A1
Foreign Referenced Citations (130)
Number Date Country
1486161 Mar 2004 CN
1961845 May 2007 CN
2902226 May 2007 CN
101146484 Mar 2008 CN
101180010 May 2008 CN
101984938 Mar 2011 CN
102869317 Jan 2013 CN
102869318 Jan 2013 CN
102869321 Jan 2013 CN
103220993 Jul 2013 CN
102639179 Oct 2014 CN
2246526 Mar 1973 DE
19532846 Mar 1997 DE
19546692 Jun 1997 DE
19857887 Jul 2000 DE
19907646 Aug 2000 DE
10049812 Apr 2002 DE
10049813 Apr 2002 DE
10049815 Apr 2002 DE
102006052564 Dec 2007 DE
102006052710 May 2008 DE
102007043830 Apr 2009 DE
102007043831 Apr 2009 DE
0103546 Mar 1984 EP
1057460 Dec 2000 EP
1088529 Apr 2001 EP
1469797 Nov 2005 EP
2111800 Oct 2009 EP
2193762 Jun 2010 EP
2278944 Feb 2011 EP
2747707 Jul 2014 EP
2918248 Sep 2015 EP
2788217 Jul 2000 FR
2815844 May 2002 FR
2003505146 Feb 2003 JP
2005515836 Jun 2005 JP
2009514628 Apr 2009 JP
2009519783 May 2009 JP
2013512765 Apr 2013 JP
1017275 Aug 2002 NL
1271508 Nov 1986 SU
9217118 Oct 1992 WO
9301768 Feb 1993 WO
9829057 Jul 1998 WO
9940964 Aug 1999 WO
9947075 Sep 1999 WO
2000018333 Apr 2000 WO
2000030550 Jun 2000 WO
2000041652 Jul 2000 WO
2000047139 Aug 2000 WO
2001035878 May 2001 WO
200149213 Jul 2001 WO
0154625 Aug 2001 WO
2001054624 Aug 2001 WO
2001056512 Aug 2001 WO
2001061289 Aug 2001 WO
2001076510 Oct 2001 WO
2001082840 Nov 2001 WO
2002004757 Jan 2002 WO
2002022054 Mar 2002 WO
2002028321 Apr 2002 WO
2002036048 May 2002 WO
2002041789 May 2002 WO
2002043620 Jun 2002 WO
2002049540 Jun 2002 WO
2002076348 Oct 2002 WO
2003003943 Jan 2003 WO
2003030776 Apr 2003 WO
03047468 Jun 2003 WO
2003049619 Jun 2003 WO
2004019825 Mar 2004 WO
2005102181 Nov 2005 WO
2006014233 Feb 2006 WO
2006034008 Mar 2006 WO
2006064490 Jun 2006 WO
2006070372 Jul 2006 WO
2006105009 Oct 2006 WO
2006113906 Oct 2006 WO
2006127756 Nov 2006 WO
2007081412 Jul 2007 WO
2007100408 Sep 2007 WO
2008005405 Jan 2008 WO
2008035337 Mar 2008 WO
2008091515 Jul 2008 WO
2008125906 Oct 2008 WO
2008147964 Dec 2008 WO
2009024859 Feb 2009 WO
2009026563 Feb 2009 WO
2009045338 Apr 2009 WO
2009132187 Oct 2009 WO
2010090878 Aug 2010 WO
2010098857 Sep 2010 WO
2010121076 Oct 2010 WO
2011017440 Feb 2011 WO
2011022658 Feb 2011 WO
2011069048 Jun 2011 WO
2011072084 Jun 2011 WO
WO-2011072084 Jun 2011 WO
2011106735 Sep 2011 WO
2011109813 Sep 2011 WO
2011159342 Dec 2011 WO
2011163275 Dec 2011 WO
2012027487 Mar 2012 WO
2012036742 Mar 2012 WO
2012095116 Jul 2012 WO
2012177942 Dec 2012 WO
2013045262 Apr 2013 WO
2013059747 Apr 2013 WO
2013096411 Jun 2013 WO
2013175468 Nov 2013 WO
2014121280 Aug 2014 WO
2014144937 Sep 2014 WO
2014162306 Oct 2014 WO
2014189974 Nov 2014 WO
2015051430 Apr 2015 WO
2015058039 Apr 2015 WO
2015063580 May 2015 WO
2015065646 May 2015 WO
2015120122 Aug 2015 WO
2015138306 Sep 2015 WO
2015173609 Nov 2015 WO
2016112085 Jul 2016 WO
2016126942 Aug 2016 WO
2016168609 Oct 2016 WO
2016196933 Dec 2016 WO
2017096157 Jun 2017 WO
2017132008 Aug 2017 WO
2017218375 Dec 2017 WO
2018005779 Jan 2018 WO
2018013515 Jan 2018 WO
Non-Patent Literature Citations (54)
Entry
US 9,155,620 B2, 10/2015, Gross et al. (withdrawn)
Webb, J. G. et al., “Percutaneous Aortic Valve Implantation Retrograde from the Femoral Artery,” Circulation, 2006, 113:842-850.
Wheatley, M.D., David J., “Valve Prostheses,” Rob & Smith's Operative Surgery, Fourth Edition, pp. 415-424, ButtenNorths 1986.
Yoganathan, A. P. et al., “The Current Status of Prosthetic Heart Valves,” In Polymetric Materials and Artificial Organs, Mar. 20, 1983, pp. 111-150, American Chemical Society.
“Shape Memory Alloys,” Retrieved from the Internet: <http://webdocs.cs.ualberta.ca/˜database/MEMS/sma.html>, Feb. 5, 2016, 3 pages.
Al Zaibag, Muayed, et al., “Percutaneous Balloon Valvotomy in Tricuspid Stenos's,” British Heart Journal, Jan. 1987, vol. 57, No. 1, pp. 51-53.
Al-Khaja, N. et al., “Eleven Years' Experience with Carpentier-Edwards Biological Valves in Relation to Survival and Complications,” European Journal of Cardiothoracic Surgery, Jun. 30, 1989, 3:305-311.
Almagor, Y. et al., “Balloon Expandable Stent Implantation in Stenotic Right Heart Valved Conduits,” Journal of the American College of Cardiology, Nov. 1, 1990, 16(6):1310-1314.
Andersen, H. R., “History of Percutaneous Aortic Valve Prosthesis,” Herz, Aug. 2009, 34(5):343-346.
Andersen, H. R., “Transluminal catheter implanted prosthetic heart valves,” International Journal of Angiology, 1998, 7(2):102-106.
Benchimol, A. et al., “Simultaneous Left Ventricular Echocardiography and Aortic Blood Velocity During Rapid Right Ventricular Pacing in Man,” The American Journal of the Medical Sciences, Jan.-Feb. 1977, 273(1):55-62.
Boudjemline, Y. et al., “Steps Toward the Percutaneous Replacement of Atrioventricular Valves: An Experimental Study,” Journal of the American College of Cardiology, Jul. 2005, 46(2):360-365.
Buckberg, G. et al., “Restoring Papillary Muscle Dimensions During Restoration In Dilated Hearts,” Interactive Cardiovascular and Thoracic Surgery, 2005, 4:475-477.
Chamberlain, G., “Ceramics Replace Body Parts,” Design News, Jun. 9, 1997, Issue 11, vol. 52, 5 pages.
Choo, S. J. et al., “Aortic Root Geometry: Pattern of Differences Between Leaflets and Sinuses of Valsava,” The Journal of Heart Valve Disease, Jul. 1999, 8:407-415.
Declaration of Malcolm J. R. Dalrymple-Hay, Nov. 9, 2012, pp. 1-11; with Curriculum Vitae, Oct. 4, 2012.
Dotter, C. T. et al., “Transluminal Treatment of Arteriosclerotic Obstruction. Description of a New Technic and a Preliminary Report of its Application,” Circulation, Nov. 1964, 30:654-670.
Drawbaugh, K., “Feature—Heart Surgeons Explore Minimally Invasive Methods,” Reuters Limited, Jul. 16, 1996, 3 pages.
Examination Report No. 1 for Australian Application No. 2014296087, dated Aug. 22, 2018, 5 pages.
G. M. Bernacca, et al., “Polyurethane Heart Valves: Fatigue Failure, Calcification, and Polyurethane Structure,” Journal of Biomedical Materials Research, Mar. 5, 1997, Issue 3, vol. 34, pp. 371-379.
Gray, H., The Aorta, Anatomy of the Human Body, 1918, Retrieved from the Internet <http://www.bartleby.com/107/142.html>, Dec. 10, 2012, 5 pages.
Gray, H., The Heart, Anatomy of the Human Body, 1918, Retrieved from the Internet <http://education.yahoo.com/reference/gray/subjects/subject/138>, Aug. 10, 2012, 9 pages.
Greenhalgh, E. S., “Design and characterization of a biomimetic prosthetic aortic heart valve,” 1994, ProQuest Dissertations and Theses, Department of Fiber and Polymer Science, North Carolina State University at Raleigh, 159 pages.
H. R. Andersen et al., “Transluminal Implantation of Artificial Heart Valves: Description of a New Expandable Aortic Valve and Initial Results with Implantation by Catheter Technique in Closed Chest Pigs,” European Heart Journal, 1992, Issue 5, vol. 13, pp. 704-708.
Inoue, K. et al., “Clinical Application of Transvenous Mitral Commissurotomy by a New Balloon Catheter,” The Journal of Thoracic and Cardiovascular Surgery, 1984, 87:394-402.
International Search Report and Written Opinion for International Application No. PCT/US2014/049218, dated Oct. 20, 2014, 14 pages.
Jin, X. Y. et al., “Aortic Root Geometry and Stentless Porcine Valve Competence,” Seminars in Thoracic and Cardiovascular Surgery, Oct. 1999, 11(4):145-150.
Kolata, G., “Device That Opens Clogged Arteries Gets a Failing Grade in a New Study,” New York Times [online], <http://www.nytimes.com/1991/01/03/health/device-that-opens-clogged-ar-teries-gets-a-faili . . . ,>, published Jan. 3, 1991,retrieved from the Internet on Feb. 5, 2016, 3 pages.
L. L. Knudsen et al., “Catheter-Implanted Prosthetic Heart Valves. Transluminal Catheter Implantation of a New Expandable Artificial Heart Valve in the Descending Thoracic Aorta in Isolated Vessels and Closed Chest Pigs,” International Journal of Artificial Organs, 1993, Issue 5, vol. 16, pp. 253-262.
Lawrence, D. D., “Percutaneous Endovascular Graft: Experimental Evaluation,” Radiology, 1987, 163:357-360.
Lozonschi, L., et al. “Transapical mitral valved stent implantation: A survival series in swine,” The Journal of Thoracic and Cardiovascular Surgery, 140(2):422-426 (Aug. 2010) published online Mar. 12, 2010, 1 page.
Lutter, Georg, et al., Mitral valved stent implantation, European Journal of Cardio-Thoracic Surgery, 2010, vol. 38, pp. 350-355.
Ma, L. et al., “Double-crowned valved stents for off-pump mitral valve replacement,” European Journal of Cardio-Thoracic Surgery, Aug. 2005, 28(2): 194-198.
Moazami, N. et al., “Transluminal aortic valve placement: A feasibility study with a newly designed collapsible aortic valve,” ASAIO Journal, Sep./Oct. 1996, 42(5):M381-M385.
Office Action for Chinese Application No. 201480050061.7, dated Feb. 3, 2017, 21 pages.
Office Action for Japanese Application No. 2016-531904, dated May 1, 2018, 11 pages.
Office Action for U.S. Appl. No. 14/224,764, dated Jul. 31, 2015, 9 pages.
Orton, C., “Mitralseal: Hybrid Transcatheter Mitral Valve Replacement,” Symposium: Small Animal Proceedings, 2011, pp. 311-312.
Pavcnik, M.D., Ph.D., Dusan, et al. “Development and Initial Experimental Evaluation of a Prosthetic Aortic Valve for Transcatheter Placement,” Cardiovascular Radiology 1992; 183:151-154.
Porstmann, W. et al., “Der Verschluß des Ductus Arteriosus Persistens ohne Thorakotomie,” Thoraxchirurgie Vaskuläre Chirurgie, Band 15, Heft 2, Stuttgart, Apr. 1967, pp. 199-203.
Rashkind, W. J., “Creation of an Atrial Septal Defect Without Thoracotomy,” The Journal of the American Medical Association, Jun. 13, 1966, 196( 11 ): 173-174.
Rashkind, W. J., “Historical Aspects of Interventional Cardiology: Past, Present, Future,” Texas Heart Institute Journal, Dec. 1986, 13(4):363-367.
Reul, H. et al., “The Geomety of the Aortic Root in Health, at Valve Disease and After Valve Replacement,” J. Biomechanics, 1990, 23(2):181-191.
Robert C. Ashton Jr., “Development of an Intraluminal Device for the Treatment of Aortic Regurgitation: Prototype and n Vitro Testing System,” Journal of Thoracic and Cardiovascular Surgery, 1996, Issue/vol. 112, pp. 979-983.
Rosch, J. et al., “The Birth, Eady Years and Future of Interventional Radiology,” J Vasc Interv Radiol., Jul. 2003, 4:841-853.
Ross, D. N., “Aortic Valve Surgery,” Guys Hospital, London, 1968, pp. 192-197.
Rousseau, E. P. M. et al., “A Mechanical Analysis of the Closed Hancock Heart Valve Prosthesis,” Journal of Biomechanics, 1998, 21(7):545-562.
Sabbah, A. N. et al., “Mechanical Factors in the Degeneration of Porcine Bioprosthetic Valves: An Overview,” Dec. 1989, Journal of Cardiac Surgery, 4(4):302-309.
Selby, M.D., J. Bayne, “Experience with New Retrieval Forceps for Foreign Body Removal in the Vascular, Urinary, and Biliary Systems,” Radiology 1990; 176:535-538.
Serruys, P.W., et al., “Stenting of Coronary Arteries. Are we the Sorcerer's Apprentice?,” European Heart Journal (1989) 10, 774-782, pp. 37-45, Jun. 13, 1989.
Sigwart, U., “An Overview of Intravascular Stents: Old and New,” Chapter 48, Interventional Cardiology, 2nd Edition, W.B. Saunders Company, Philadelphia, PA, © 1994, 1990, pp. 803-815.
Tofeig, M. et al., “Transcatheter Closure of a Mid-Muscular Ventricular Septal Defect with an Amplatzer VSD Occluder Device,” Heart, 1999, 81:438-440.
Uchida, Barry T., et al., “Modifications of Gianturco Expandable Wire Stents,” AJR:150, May 1988, Dec. 3, 1987, pp. 1185-1187.
Watt, A.H., et al. “Intravenous Adenosine in the Treatment of Supraventricular Tachycardia; a Dose-Ranging Study and Interaction with Dipyridamole,” British Journal of Clinical Pharmacology (1986), 21, pp. 227-230.
Related Publications (1)
Number Date Country
20200179112 A1 Jun 2020 US
Provisional Applications (2)
Number Date Country
61895975 Oct 2013 US
61861356 Aug 2013 US
Divisions (1)
Number Date Country
Parent 15001727 Jan 2016 US
Child 16790875 US
Continuations (1)
Number Date Country
Parent PCT/US2014/049218 Jul 2014 US
Child 15001727 US
Continuation in Parts (1)
Number Date Country
Parent 14224764 Mar 2014 US
Child PCT/US2014/049218 US